EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months

Kristina S Boye, Jérémie Lebrec, Anne Dib, Elke Heitmann, Marco Orsini Federici, Maria Yu, Hélène Sapin, Annabel Barrett, Bruno Guerci, Francesco Giorgino iD, Martin Füchtenbusch, Luis-Emilio García-Pérez iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15145 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Kristina S Boye und 11 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To report health‐related patient‐reported outcomes (PROs) in people with type 2 diabetes (T2D) initiating their first injectable glucose‐lowering medication (GLM) with two commonly prescribed glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) from the prospective, observational TROPHIES study (The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients). Materials and Methods TROPHIES was a two‐cohort, 24‐month study conducted in France, Germany and Italy. Adults with a T2D diagnosis, naïve to injectable treatment for T2D and prescribed dulaglutide or liraglutide as their first injectable GLM, were eligible for inclusion. Study objectives included describing the following PROs associated with the treatment of T2D with GLP‐1RAs: health‐related quality of life; impact of weight on self‐perception; life and work productivity; and patient satisfaction with treatment and injection device. Additional analyses formally compared PRO measures between the treatment cohorts.

Results

Overall, improvements from baseline in PRO scores were observed among people who started dulaglutide or liraglutide. A more pronounced trend of improvement was observed in the dulaglutide cohort for changes from baseline in treatment satisfaction and impact of weight on self‐perception, supported by statistically significant differences between treatment cohorts in additional comparative analyses at 12, 18 and 24 months. More positive patient perceptions of the injection device were observed with dulaglutide than with liraglutide.

Conclusions

Improvements in PROs observed in TROPHIES, which were more evident with dulaglutide than liraglutide, reflect a relevant clinical benefit. From the patients’ perspective, satisfaction, and confidence in continuing treatment with GLP‐1RAs is likely to contribute to long‐term treatment persistence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2AdultHumansGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsLiraglutideOutcome Assessment, Health CarePatient Reported Outcome MeasuresProspective StudiesQuality of LifeRecombinant Fusion ProteinsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

dulaglutideglucagon-like peptide-1 receptor agonistsliraglutidepatient-reported outcomestype 2 diabetes

Substanzen

dulaglutideGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsLiraglutideRecombinant Fusion ProteinsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • HaaPACS GmbH, Schriesheim, Germany.
  • University Hospital of Nancy, Vandoeuvre Lès Nancy, France.
  • University of Bari Aldo Moro, Bari, Italy.
  • Marienplatz Diabetes Centre, Munich, Germany.

ORCID-Profile: Francesco Giorgino, Luis-Emilio García-Pérez

Förderung

  • Eli Lilly and Company

Zitieren

APA

Boye, K. S., Lebrec, J., Dib, A., Heitmann, E., Federici, M. O., Yu, M., Sapin, H., Barrett, A., Guerci, B., Giorgino, F., Füchtenbusch, M., & García-Pérez, L. E. (2023). The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15145

Vancouver

Boye KS, Lebrec J, Dib A, Heitmann E, Federici MO, Yu M, et al. The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15145

BibTeX
@article{Boye2023,
  author = {Boye, Kristina S and Lebrec, Jérémie and Dib, Anne and Heitmann, Elke and Federici, Marco Orsini and Yu, Maria and Sapin, Hélène and Barrett, Annabel and Guerci, Bruno and Giorgino, Francesco and Füchtenbusch, Martin and García-Pérez, Luis-Emilio},
  title = {The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15145}
}
Kostenlos starten →